Mystic Pharmaceuticals has been granted US Patent 7,669,597, a key technology of its VRx2 drug delivery platform. The VRx2 Delivery Platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics.
The issued patent covers Mystic’s unit dose blister technology for packaging of drugs or biologics that have been freeze dried to powder form to improve stability, reduce the need for cold chain management and enable auto-reconstitution to a liquid form at the time of administration.
Mystic said that its patented unit dose blister technology enables freeze dried drugs to be pre-packaged in intranasal or ophthalmic delivery systems and automatically reconstituted and self-administered by the consumer with the push of a button.
Timothy Sullivan, president and CEO of Mystic, said: “Mystic’s technology will simplify and accelerate the packaging, deployment and delivery of drugs and biologics to protect the public safety in a crisis situation.”
CJ Peters, director for Biodefense in the Center for Biodefense and Emerging Infectious Diseases at the University of Texas Medical Branch, said: “One of the primary applications for this technology will be to develop needle-free vaccines for pandemic and bioterror threats that are safer, easier and less costly to produce and deploy.”